Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Active, not recruiting, industry sponsors, Psychiatry, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed907
13 trials
Showing 1 to 13, recently updated first.
- Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Pivotal-lookingActive, not recruiting
Supernus Pharmaceuticals, Inc.Industry
NCT02736656 · 1,400 participants (planned) · Start Feb 2, 2016 · Primary completion Dec 2026
Drug: SPN-812 · For: Attention-Deficit/Hyperactivity Disorder
Sites: Little Rock, Arkansas; Long Beach, California; Colorado Springs, Colorado · 16 sites in all
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)Pivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT07076407 · 450 participants (planned) · Start Jul 8, 2025 · Primary completion May 2027
Drug: Azetukalner; Placebo · For: Major Depressive Disorder
Sites: Dothan, Alabama; Huntsville, Alabama; Bentonville, Arkansas · 50 sites in all
- Study on the Efficacy and Safety of QLM1016 in SchizophreniaPivotal-lookingActive, not recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06799559 · 402 participants (planned) · Start Oct 2, 2025 · Primary completion Oct 23, 2026
Drug: 3-6mg QLM1016; 10-20 mg Aripiprazole oral solution film · For: Schizophrenia
Sites: Jinan, China
- An Open-Label Study of Azetukalner in Major Depressive DisorderPivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT06922110 · 460 participants (planned) · Start Mar 18, 2025 · Primary completion Jan 2027
Drug: Azetukalner · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Bryant, Arkansas; Little Rock, Arkansas · 71 sites in all
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)Pivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT07172516 · 400 participants (planned) · Start Aug 8, 2025 · Primary completion Jun 2028
Drug: Azetukalner; Placebo · For: Bipolar Disorder; Bipolar Depression; Bipolar I Disorder and 1 more
Sites: Tucson, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 44 sites in all
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)Pivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT07217860 · 400 participants (planned) · Start Oct 30, 2025 · Primary completion Jun 2029
Drug: Azetukalner · For: Bipolar Depression; Bipolar I Disorder; Bipolar Disorder and 1 more
Sites: Little Rock, Arkansas; Rogers, Arkansas; Bellflower, California · 20 sites in all
- A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaPivotal-lookingActive, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06894212 · 538 participants · Start Feb 28, 2025 · Primary completion Oct 20, 2026
Drug: SEP-363856 · For: Schizophrenia
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Rogers, Arkansas · 73 sites in all
- A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)Pivotal-lookingActive, not recruiting
Definium Therapeutics US, Inc.Industry
NCT06741228 · 214 participants · Start Dec 11, 2024 · Primary completion Jul 15, 2026
Drug: DT120 · For: Generalized Anxiety Disorder
Sites: Gilbert, Arizona; Scottsdale, Arizona; La Jolla, California · 34 sites in all
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)Pivotal-lookingActive, not recruiting
Definium Therapeutics US, Inc.Industry
NCT06809595 · 245 participants · Start Jan 29, 2025 · Primary completion Aug 13, 2026
Drug: DT120 · For: Generalized Anxiety Disorder
Sites: Little Rock, Arkansas; Los Angeles, California; Bradenton, Florida · 36 sites in all
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)Pivotal-lookingActive, not recruiting
Definium Therapeutics US, Inc.Industry
NCT06941844 · 149 participants · Start Apr 14, 2025 · Primary completion May 20, 2026
Drug: DT120 · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; La Jolla, California; Santa Monica, California · 22 sites in all
- Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderPivotal-lookingActive, not recruiting
Vanda PharmaceuticalsIndustry
NCT07221578 · 500 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 2026
Drug: VQW-765; Placebo · For: Social Anxiety Disorder (SAD)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Encino, California · 30 sites in all
- Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDPivotal-lookingActive, not recruiting
COMPASS PathwaysIndustry
NCT05711940 · 572 participants · Start Feb 14, 2023 · Primary completion Nov 13, 2025
Drug: Psilocybin · For: Treatment Resistant Depression
Sites: Gilbert, Arizona; Bellflower, California; Encino, California · 116 sites in all
- A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous PropofolPivotal-lookingActive, not recruiting
Sedana MedicalIndustry
NCT06809218 · 312 participants (planned) · Start Apr 22, 2022 · Primary completion Nov 14, 2024
Drug: Inhaled isoflurane administered by Sedaconda ACD-S; Intravenous infusion of propofol · For: Post-Intensive Care Syndrome; Sedation
Sites: Nashville, Tennessee
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.